References
- Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22:504–509.
- Merrill JT, Buyon JP, Utset T. A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2014;44:e1–2.
- Fattah Z, Isenberg DA. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opin Biol Ther. 2014;14:311–326.
- Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis. 2011;70(Suppl 1):i64–i66.
- Wallace DJ, Stoh W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–1178.
- Wofsy D. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis. 2013;72(Suppl 2):ii66–8.
- Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939.
- Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun. 2014;54:60–71.
- Francis L, Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother. 2009;10:1481–1494.
- Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15:366–370.
- Wallace DJ. Antimalarials—the ‘real’ advance in lupus. Lupus. 2001;10:385–387.
- Kamal A, Khamashta M. The efficacy of novel B-cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13:1094–1101.
- Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol. 2012;2012:578641.
- Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus (NCT00714116). ClinicalTrials.gov.; [Last accessed 7 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT00714116?term=NCT00714116&rank=1
- Illidge T, Klein C, Sehn LH, et al. Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treat Rev. 2015;pii: S0305-7372(15)00148-6. [Epub ahead of print]. doi:10.1016/j.ctrv.2015.07.003.
- A Study to Evaluate the Safety and Efficacy of Obinutuzumab, an Antibody Targeting Certain Types of Immune Cells, in Participants With Lupus Nephritis (LN) (NCT02550652). ClinicalTrials.gov.; [Last accessed 8 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT02550652
- Furtado J, Isenberg DA. B-cell elimination in systemic lupus erythematosus. Clin Immunol. 2013;146:90–103.
- Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489–1503.
- Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–2589.
- Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011;50:1401–1408.
- Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222–233.
- Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–1226.
- Bertsias GK, Tektonidou M, Amoura Z, et al. Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.
- Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, includingbiological immunosuppressive agents, in Germany, Austria and Switzerland–a consensus report. Lupus. 2012;21:386–401.
- Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280–1286.
- Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis (RITUXILUP) (NCT01773616). ClinicalTrials.gov; [Last accessed 1 Feb 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT01773616?term=NCT01773616&rank=1
- Rituximab and Belimumab for Lupus Nephritis (NCT02260934). ClinicalTrials.gov.; [Last accessed 1 February 2016]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02260934?term=NCT02260934&rank=1
- Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) (NCT00539838). ClinicalTrials.gov.; [Last accessed 7 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00539838?term=NCT00539838&rank=1
- A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) (NCT00626197). ClinicalTrials.gov.; [Last accessed 7 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00626197?term=NCT00626197&rank=1
- Wallace DJ, Hobbs K, Houssiau F, et al. Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients. Ann Rheum Dis. 2008;67(Suppl II):212.
- Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183–190.
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1) (NCT01262365). ClinicalTrials.gov.; [Last accessed 7 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01262365?term=NCT01262365&rank=1
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) (NCT01261793). ClinicalTrials.gov.; [Last accessed 7 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01261793?term=NCT01261793&rank=1
- Clowse MEB, Wallace DJ, Furie R, et al. Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: results from Two Phase 3 Randomized, Placebo-Controlled Trials. ACR Abstract 2015; Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-epratuzumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-from-two-phase-3-randomized-placebo-controlled-trials/
- Ritterhouse LL, Crowe SR, Niewold TB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011;63:3931–3941.
- Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–4150.
- Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14:R33.
- Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006–2015.
- Selmi C, Generali E, Massarotti M, et al. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60:277–288.
- Isenberg D, Merrill J, Hoffman R et al. OP0184 efficacy and safety of tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52-week, multicenter, randomized, placebo-controlled trials. EULAR Abstract 2015. Available from: http://ard.bmj.com/content/74/Suppl_2/141.1.
- A Study of LY2127399 in Patients With Systemic Lupus Erythematosus. (NCT01205438). ClinicalTrials.gov; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01205438?term=NCT01205438&rank=1
- An Open-Label Study in Participants With Systemic Lupus Erythematosus (Illuminate-X). (NCT01488708). ClinicalTrials.gov; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01488708?term=NCT01205438&rank=2
- Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B-cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667–1675.
- Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–1838.
- Bruce IN, Urowitz M, Van Vollenhoven R et al. 5-year organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. EULAR Abstract 2015. Available from: http://www.abstracts2view.com/eular/view.php?nu=EULAR15L_OP0186
- Liu Z, Zou Y, Davidson A. Plasma cells in systemic lupus erythematosus: the long and short of it all. Eur J Immunol. 2011;41:588–591.
- Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64:493–503.
- Velcade for Proliferative Lupus Nephritis. (NCT01169857). ClinicalTrials.gov.; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01169857?term=NCT01169857&rank=1
- Seavey MM, Lu LD, Stump KL, et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12:257–270.
- Kang H-K, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007;178:7849–7858.
- Amarilyo G, Hahn B, La Cava A. Preclinical studies with synthetic peptides in systemic lupus erythematosus. Front Biosci (Landmark Ed). 2012;17:1940–1947.
- Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
- Skaggs BJ, Lourenço EV, Hahn BH. Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice. Lupus. 2011;20:912–920.
- Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol. 2013;149:365e78.
- Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008;58:3873–3883.
- Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013;72:1830–1835.
- Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015;2:e000104.
- Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol. 2003;171:489–497.
- Navarra SV. Immune therapy of lupus: what is on the horizon? Nephrol Dial Transplant. 2006;21:579–581.
- Xiong W, Lahita RG. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskeletal Dis. 2011;3:255–266.
- Haubitz M. New and emerging treatment approaches to lupus. Biologics. 2010;4:263–271.
- Furie R, Nicholls K, Cheng -T-T, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66:379–389.
- ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 2014;66:3096–3104.
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. (NCT01714817). ClinicalTrials.gov; [Last accessed 15 Sep 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01714817?term=Abatacept&rank=46
- Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) (NCT00094380). ClinicalTrials.gov.; [Last accessed 8 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT00094380?term=NCT00094380&rank=1
- A Study of AMG 557 in Adults With Systemic Lupus Erythematosus. (NCT00774943). ClinicalTrials.gov.; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT00774943?term=NCT00774943&rank=1
- Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–727.
- Tocoian A, Buchan P, Kirby H, et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015;24:1045–1056.
- Postal M, Appenzeller S. The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine. 2011;56:537–543.
- La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010;2:575–582.
- Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–552.
- Thanarajasingam U, Niewold TB. Sirukumab: a novel therapy for lupus nephritis? Expert Opin Investig Drugs. 2014;23:1449–1455.
- Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65:2661–2671.
- An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis. (NCT01273389). ClinicalTrials.gov; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01273389?term=NCT01273389&rank=1
- Smolen J, Popa S, Szombati I et al. OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity. EULAR Abstract 2015. Available from: http://ard.bmj.com/content/74/Suppl_2/141.2.abstract.
- Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Lupus. 2015;24:351–363.
- Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl2):ii116–23.
- An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE). (NCT01689025). ClinicalTrials.gov.; [Last accessed 8 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01689025?term=NCT01689025&rank=1
- Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196–202.
- Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011–1021.
- Khamashta M, Merrill JT, Werth VP, et al. Safety and efficacy of sifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe Systemic Lupus Erythematosus (SLE). ACR Annual Meeting Late-Breaking Abstract 2014. Available from: http://acrabstracts.org/abstracts/safety-and-efficacy-of-sifalimumab-an-anti-ifn-alpha-monoclonal-antibody-in-a-phase-2b-study-of-moderate-to-severe-systemic-lupus-erythematosus-sle/
- Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044–1053.
- Ko K, Koldobskaya Y, Rosenzweig E, et al. Activation of the interferon pathway is dependent upon autoantibodies in african-american sle patients, but not in European-American SLE patients. Front Immunol. 2013;4:309.
- Sharma S, Jin Z, Rosenzweig E, et al. Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J Autoimmun. 2015;60:51–58.
- Wang B, Higgs BW, Chang L, et al Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Clin Pharmacol Ther. 2013;93:483–492.
- Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus. (NCT01559090). ClinicalTrials.gov.; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01559090?term=MEDI-546&rank=2
- A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus. (NCT01438489). ClinicalTrials.gov.; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01438489?term=MEDI-546&rank=3
- An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of Systemic Lupus Erythematosus, in Adults. (NCT01753193). ClinicalTrials.gov.; [Last accessed 8 April 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01753193?term=MEDI-546&rank=4
- Furie R, Merrill JT, Werth VP, et al. Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE). ACR Abstract 2015 Available from: http://acrabstracts.org/abstract/anifrolumab-an-anti-interferon-alpha-receptor-monoclonal-antibody-in-moderate-to-severe-systemic-lupus-erythematosus-sle/
- Chang L, Wang L, Brohawn P et al. Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials. ACR Abstract 2014. Available from: http://acrabstracts.org/abstracts/target-modulation-of-a-type-i-interferon-ifn-gene-signature-with-sifalimumab-or-anifrolumab-in-systemic-lupus-erythematosus-sle-patients-in-two-open-label-phase-2-japanese-trials/
- AstraZeneca presents positive new data on anifrolumab in lupus at American College of Rheumatology Annual Scientific Meeting. 2015. Available from: https://www.astrazeneca.com/our-company/media-centre/press-releases/2015/AstraZeneca-presents-positive-new-data-on-anifrolumab-in-lupus-at-American-College-of-Rheumatology-Annual-Scientific-Meeting-10112015.html
- Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. 2013;65:447–456.
- Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127:303-12;quiz 313-4.
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus. (NCT02535689). linicalTrials.gov.; [Last accessed 5 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02535689?term=Tofacitinib&rank=5
- Yap DY, Ma MK, Mok MM, et al. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology (Oxford). 2014;53:2232–2237.
- Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75:30–36.
- Prospective Study of Rapamycin for the Treatment of SLE (Rapamune). (NCT00779194). ClinicalTrials.gov; [Last accessed 5 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT00779194?term=NCT00779194&rank=1
- Jensen MA, Niewold TB. Interferon regulatory factors: critical mediators of human lupus. Transl Res. 2015;165:283–295.
- RSLV-132 Biologic Proof-of-Concept in Systemic Lupus Erythematosus. (NCT02194400). ClinicalTrials.gov.; [Last accessed 15 Sep 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02194400?term=RSLV-132&rank=1
- Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus. (NCT02106897). ClinicalTrials.gov.; [Last accessed 15 Sep 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02106897
- Li J, Wang X, Zhang F, et al. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol Ther. 2013;138:441–451.
- First Safety Study in Humans of a Single Dose of CPG 52364. (NCT00547014). ClinicalTrials.gov.; [Last accessed 5 Oct 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT00547014?term=CpG-52364&rank=1
- Lupus Clinical Investigators Network (LuCINTM). [Last accessed 5 Oct 2015]. Available from: http://www.ampelbiosolutions.com/lrxl-stat
- Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. J Autoimmun. 2015;64:125–136.